Standard BioTools Inc LAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
-
Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)
-
Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Standard BioTools to Participate in Upcoming Investor Conferences
-
Standard BioTools Announces Senior Leadership Changes
-
Standard BioTools Reports Second Quarter 2024 Financial Results
-
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
-
SomaLogic's stock surges as it agrees to be bought by Standard BioTools in all-stock merger
Trading Information
- Previous Close Price
- $1.83
- Day Range
- $1.82–1.91
- 52-Week Range
- $1.21–3.04
- Bid/Ask
- $1.89 / $1.91
- Market Cap
- $705.19 Mil
- Volume/Avg
- 1.6 Mil / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 5.82%
Company Profile
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 539
- Website
- https://www.standardbio.com
Comparables
Valuation
|
Metric
|
LAB
|
SERA
|
688606
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 26.11 |
Price/Book Value | 1.38 | 4.14 | 1.24 |
Price/Sales | 2.88 | 2,213.92 | 6.19 |
Price/Cash Flow | — | — | 18.86 |
Price/Earnings
LAB
SERA
688606
Financial Strength
|
Metric
|
LAB
|
SERA
|
688606
|
|---|---|---|---|
Quick Ratio | 3.45 | 2.06 | 7.73 |
Current Ratio | 3.88 | 2.08 | 8.43 |
Interest Coverage | — | −806.69 | 235.62 |
Quick Ratio
LAB
SERA
688606
Profitability
|
Metric
|
LAB
|
SERA
|
688606
|
|---|---|---|---|
Return on Assets (Normalized) | −17.43% | −27.67% | 4.14% |
Return on Equity (Normalized) | −62.87% | −36.00% | 4.49% |
Return on Invested Capital (Normalized) | −39.57% | −38.33% | 3.52% |
Return on Assets
LAB
SERA
688606
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Nnzjqsrrj | Kjdqz | $196.1 Bil | |||
| Stryker Corp
SYK
| Dhhjgzmn | Ksk | $137.7 Bil | |||
| Boston Scientific Corp
BSX
| Pprxxnm | Jztjfnj | $122.3 Bil | |||
| Medtronic PLC
MDT
| Qksrzyt | Zkplxw | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Sjkbtptmhj | Tvdxvk | $39.6 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Xhmp | Zblh | $29.3 Bil | |||
| DexCom Inc
DXCM
| Lqdwdcmb | Yykr | $27.1 Bil | |||
| Steris PLC
STE
| Qvzgybhyn | Gxwfzx | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Bkjjsdygn | Dcrlf | $21.9 Bil | |||
| Insulet Corp
PODD
| Wwxzytly | Zmprft | $16.5 Bil |
United States